These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26481616)

  • 1. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study.
    Chen VC; Liao YT; Lai TJ; Lane HY; Shao WC; Dewey M; Lee CT; Lu ML
    Schizophr Res; 2015 Dec; 169(1-3):406-411. PubMed ID: 26481616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
    Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
    Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes.
    Weinmann S; Janssen B; Gaebel W
    J Clin Psychiatry; 2004 Aug; 65(8):1099-105. PubMed ID: 15323596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study.
    Fang SC; Huang CY; Liao DL; Hsu CC; Shao YJ
    Schizophr Res; 2019 Oct; 212():150-156. PubMed ID: 31395489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Bindman J; Leese M; Schene A; Becker T; Angermeyer MC; Koeter M; Gray R; Tansella M
    Int Clin Psychopharmacol; 2006 Mar; 21(2):73-9. PubMed ID: 16421457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.
    Xue Q; Xiong X; Feng Y; Yao L; Chen S; Xiang L
    Int Clin Psychopharmacol; 2014 Sep; 29(5):288-95. PubMed ID: 24323200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in antipsychotic usage pattern and risk of relapse in older patients with schizophrenia.
    Talaslahti T; Alanen HM; Hakko H; Isohanni M; Häkkinen U; Leinonen E
    Int J Geriatr Psychiatry; 2013 Dec; 28(12):1305-11. PubMed ID: 23558986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
    Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
    Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic patterns in outpatients with schizophrenia in China: A cross sectional study.
    Guo X; Yu H; Wang H
    Medicine (Baltimore); 2021 Aug; 100(32):e26912. PubMed ID: 34397928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Female schizophrenia patients and risk of breast cancer: A population-based cohort study.
    Wu Chou AI; Wang YC; Lin CL; Kao CH
    Schizophr Res; 2017 Oct; 188():165-171. PubMed ID: 28108225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006.
    Wu CS; Lin YJ; Feng J
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):989-96. PubMed ID: 22416032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.
    Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU
    Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence patterns with first- versus second-generation antipsychotics for newly diagnosed schizophrenia in Taiwan.
    Chang CM; Wu KY; Liang HY; Wu EC; Chen CY; Wu CS; Chen SJ; Chang TK; Tsai HJ
    Psychiatr Serv; 2012; 63(5):504-7. PubMed ID: 22549537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.